Collection of data from patients with ANCA-associated vasculitis
Official title: Biocollection of Patients With ANCA Associated Vasculitis Diagnosed Within the CERAINO Autoimmune Disease Reference Center, Part of the Global BRAISE Project (B-dependent Rare AutoImmune DiseaSES
Run by University Hospital, Brest · NCT05364892 · Data updated 2026-11-12
This study is collecting information and samples from people with ANCA-associated vasculitis to see if they can find out who is more likely to have a relapse and who might be able to stop their medications safely.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest, Brest) |
| Status | Recruiting |
| Started | October 27, 2022 |
| Main results expected | October 27, 2032 |
| Study ends | October 27, 2032 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT05364892 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults diagnosed with ANCA-associated vasculitis who are being treated at the reference center for rare autoimmune diseases.
✕Probably not a fit
Patients who are minors, unable to consent, or have severe anemia (Hb < 7g/dL) may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect standardized data from patients diagnosed with ANCA-associated vasculitis, a rare and severe autoimmune disease. By gathering blood, fecal, and urinary samples, along with patient questionnaires, the research seeks to identify predictors of disease relapse and other complications. The long-term goal is to improve patient management by determining which individuals are at higher risk for relapse and which can safely discontinue immunosuppressive treatments. This multi-year follow-up will enhance understanding of the disease's characteristics and its impact on patient prognosis.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for patients with ANCA-associated vasculitis, reducing the risk of relapse and treatment side effects.
How similar studies have gone: While studies on ANCA-associated vasculitis exist, this approach of comprehensive data collection for predicting relapse is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patients with no upper age limit. * Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest. * Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference. * Patient affiliated with Social Security * Patient who has signed written informed consent Exclusion Criteria: * Minor * Patients unable to consent. * Patients refusing to participate in research * Patient under legal protection (tutelage, curatorship) * Pregnant or lactating women * Hemoglobin (Hb) \< 7g/dL
Where it's running
-
CHRU de Brest - Service de rhumatologie
Brest, Brest, France Recruiting
Study contacts
- Study coordinator: Divi CORNEC
- Email: divi.cornec@chu-brest.fr
- Phone: (0)2 98 34 72 64
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
-
Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases
This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.
-
Gallium-68 FAPI PET/CT imaging for people with ANCA-associated vasculitis
This project will test whether Gallium-68 FAPI PET/CT scans can detect lung and kidney involvement in adults with ANCA-associated vasculitis.
-
Imaging in Inflammatory Heart Diseases linked to autoimmune disorders
This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.
-
Epithelial Dysmetabolism and Kidney Fibrosis in ANCA Vasculitis
This study tests whether alterations in tubulo-interstitial metabolism relate to how quickly kidney function deteriorates in people with ANCA-associated vasculitis compared to other nephropathies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.